Compare NBN & AQST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NBN | AQST |
|---|---|---|
| Founded | 1872 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 836.7M | 707.6M |
| IPO Year | N/A | 2018 |
| Metric | NBN | AQST |
|---|---|---|
| Price | $124.45 | $4.08 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $102.00 | $8.83 |
| AVG Volume (30 Days) | 113.4K | ★ 9.9M |
| Earning Date | 01-26-2026 | 03-04-2026 |
| Dividend Yield | ★ 0.03% | N/A |
| EPS Growth | ★ 20.54 | N/A |
| EPS | ★ 10.36 | N/A |
| Revenue | ★ $213,090,000.00 | $43,397,000.00 |
| Revenue This Year | $11.59 | N/A |
| Revenue Next Year | $11.26 | $17.63 |
| P/E Ratio | $12.09 | ★ N/A |
| Revenue Growth | ★ 23.79 | N/A |
| 52 Week Low | $78.17 | $2.12 |
| 52 Week High | $126.26 | $7.55 |
| Indicator | NBN | AQST |
|---|---|---|
| Relative Strength Index (RSI) | 66.47 | 45.40 |
| Support Level | $118.94 | $3.78 |
| Resistance Level | $126.26 | $4.39 |
| Average True Range (ATR) | 4.75 | 0.25 |
| MACD | 0.33 | 0.16 |
| Stochastic Oscillator | 83.88 | 66.73 |
Northeast Bank provides banking and financial services to individual and corporate customers in the United States. The firm conducts its loan-related activities through two primary channels: the Community Banking Division, and the Small Business Administration (SBA) National Division. Its loan portfolio comprises residential mortgage loans; multi-family and other commercial real estate loans; commercial and industrial loans, consumer loans, and small business administration loans. The firm also provides telephone banking, online banking, mobile banking, and remote deposit capture services. The revenue of the company is derived principally from interest and dividends from the bank.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.